CTI was founded in 1991, and currently employs approximately 268 people from its two Seattle, Washington facilities. CTI's strategy is to use the polymer technology to build a portfolio of potentially safer and more effective versions of well-known anti-cancer agents. They believe that their polymer drug development program may lower the risks inherent in developing new drugs because they are linking polymers to well defined and widely used chemotherapy drugs. They are initially focusing their development efforts on applying PG to two classes of anticancer drugs, taxanes and camptothecins.